For instance, as one of the most prevalent biomarkers used in liquid biopsy, ctDNA is now widely used to aid in the selection of NSCLC patients who might benefit from epidermal growth factor receptor (EGFR)-targeted therapy (33). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.